New study tests safety of TALZENNA in Tough-to-Treat breast cancer
NCT ID NCT06735742
First seen Oct 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study looks at the safety of the drug TALZENNA in people with a specific type of breast cancer (BRCA mutation-positive, HER2-negative) that cannot be removed by surgery or has returned after treatment. Participants must have had chemotherapy before and never taken TALZENNA. They will take the drug as prescribed and be monitored for side effects for up to 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Japan
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.